Substance Use Disorder (SUD) Education: DEA Requirement

• ACP Pain Management 7: Opioid Use Disorder 5 CME
  This interactive training module provides background information necessary to support clinicians in their care for persons with opioid use disorder (OUD), including persons with coexisting chronic pain.

• SUD Presentations from 2023 Internal Medicine Meeting 2.5 CME
  Captured from Internal Medicine Meeting 2023, this video bundle package provides 2.5 hours of high-yield video content covering strategies and management options for treating substance use disorder.
• SUD Presentations from 2022 Internal Medicine Meeting 3 CME
  Captured from Internal Medicine Meeting 2022, this video bundle package provides 3 hours of high-yield video content covering strategies and management options for treating substance use disorder.
• X-Express: The ABCs of Prescribing Buprenorphine 1 CME
  This highly practical one-hour video course provides an overview of the role buprenorphine plays in the management of opioid use disorder.

• Evidence-Based Care of Substance Use Disorders 1 CME
  In this episode of Annals On Call, Dr. Centor discusses current thinking about the appropriate treatment of patients with substance use disorder with Dr. Stefan Kertesz.
• Opioid Use Disorder 1 CME
  In this episode of Annals On Call, Dr. Centor discusses the care of patients with opioid use disorder with Dr. Jessica Taylor.
• 5 Pearls on Stigma in Opioid Use Disorder 1 CME
  In this episode of Core IM, the team will discuss how language can contribute to increasing or decreasing the stigma surrounding OUD, as well as physicians’ potential lack of ability to apply culturally relevant approaches to SUD treatment and management.
• Underuse of Thiamine in Patients With Alcohol Use Disorder in the Intensive Care Unit 1 CME
  In this episode of Annals On Call, Dr. Centor discusses the underuse of thiamine in critically ill patients with alcohol use disorder with Dr. Michael Donnino.
• The Breadth of Addiction Medicine 0.5 CME
  This episode of The DEI Shift explores the broad and timely topic of addiction with Dr. Chwen-Yuen Angie Chen.

• Xylazine Adulteration of the Heroin–Fentanyl Drug Supply, A Narrative Review 0.5 CME
  Clinical experience along with the available pertinent research were used to review Xylazine, an animal sedative, and provide guidance on the care of patients exposed to Xylazine, published in Annals of Internal Medicine. After reading the article, follow instructions on the Point-of-Care CME page to claim credit.
• Alcohol Use 1.5 CME
  Unhealthy alcohol use—the consumption of alcohol at a level that has caused or has the potential to cause adverse physical, psychological, or social consequences—is common, underrecognized, and undertreated. For example, data from the 2020 National Survey on Drug Use and Health indicate that 7.0% of adults reported heavy alcohol use in the previous month, and only 4.2% of adults with alcohol use disorder received treatment. Primary care is an important setting for optimizing screening and treatment of unhealthy alcohol use to promote individual and public health.
• Opioid Use Disorder 1.5 CME
  Opioid use disorder (OUD) is a treatable chronic disorder with episodes of remission and recurrence characterized by loss of control of opioid use, compulsive use, and continued use despite harms. If untreated, OUD is associated with significant morbidity and mortality. Buprenorphine and methadone reduce fatal and nonfatal opioid overdose and infectious complications of OUD and are the first-line treatment options. Physicians have an important role to play in diagnosing OUD and its comorbidities, offering evidence-based treatment, and delivering overdose prevention and other harm reduction services to people who continue to use opioids. Interdisciplinary office-based addiction treatment programs support high-quality OUD care.
• Care of the Patient Using Cannabis 1.5 CME
  The past 2 decades have seen a revolution in legal access to cannabis, driven largely by activists and business interests. As a result, the population of cannabis users nationwide—especially daily users—has grown significantly. An estimated 4.5–7 million persons in the United States now meet criteria for cannabis use disorder annually. This article focuses on the effects of cannabis use, intoxication, and withdrawal while also reviewing the developmental pathways of cannabis use disorder as well as evidence-based pharmacologic and psychosocial treatments.

Beginning on June 27th, 2023, the DEA will require one-time attestation (checking a box on the online registration form) of training on management of substance use disorders (SUDs) prior to renewal of a DEA registration. The DEA has released guidance on the new one-time requirement for completion of eight hours of training on the treatment and management of patients with opioid or other SUDs.

Yes! As an ACCME-accredited (with commendation) organization, ACP’s offerings qualify on the basis of the stipulation stating that “any other organization accredited by the Accreditation Council for Continuing Medical Education (AACCME)…directly or through an organization accredited by a State medical society that is recognized by the ACCME…”

Yes. Past training on the treatment and management of patients with SUD via ACP can count towards meeting the requirement even if prior to the enactment of this new training obligation. Additionally, the training does not have to occur in one session. It can be cumulative across multiple sessions that equal eight hours of training.

The attestation will only be solicited by the DEA upon registration (new or renewal) after the implementation date of June 27th, 2023. So, if you renewed your license in January of 2023, you would not be required to attest to your participation in training until the time of your next renewal.

Yes. Past DATA-Waived trainings count towards a DEA registrant’s 8-hour training requirement. Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe medications, like buprenorphine, for the treatment of opioid use disorder (OUD). The education requirement refers to substance use disorders and not exclusively opioid use disorder; therefore the 8 hours can be completed cumulatively in a variety of areas comprising SUD and across multiple sessions that total 8 hours of training.

The DEA currently accepts attestation of recent training only if you graduated from an accredited US medical school (MD or DO) within 5 years of June 27, 2023. During your school years you must have successfully completed a comprehensive curriculum that included at least eight hours of training on managing opioid or other SUDs, including use of all drugs approved by the FDA for SUD treatment. International medical graduates and graduates of US medical schools without comprehensive SUD curriculum should complete accredited CME content, even if CME hours are not formally submitted, to meet the attestation obligations.

According to the DEA FAQs page, If you never plan on administering, dispensing or prescribing a controlled substance in your practice, you are not required to hold a DEA registration. ACP recommends you review the FAQ page of the DEA website for more information.